In particular, molecular monitoring of BCR-ABL transcript levels by real-time quantitative PCR (RQ PCR) is progressively becoming the most useful and precise way to monitor CML patients. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.